arrow_back Trending Legislation
Share share

Expedited Biosimilar Access: Streamlined Clinical Study Requirements

This act aims to accelerate the market entry of biosimilar drugs, which are more affordable alternatives to expensive biological medicines. By simplifying clinical study requirements, citizens may gain faster access to necessary therapies, potentially lowering treatment costs and increasing drug availability.
Key points
Simplified Clinical Studies: Biosimilar drugs will not always require tests for immune responses, drug action in the body, or comparative efficacy.
Faster Drug Approval: The changes could reduce the time needed for biosimilar drugs to be approved for sale.
Potential Lower Treatment Costs: Greater availability of cheaper alternatives may lead to lower drug expenditures for patients and healthcare systems.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Expedited Access to Biosimilars Act
Print number: S 1414
Sponsor: Sen. Paul, Rand [R-KY]
Process start date: 2025-04-10
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Expedited Biosimilar Access: Streamlined Clinical Study Requirements

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1414.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-04-10.

What are the main provisions?

Key points include:

  • Simplified Clinical Studies: Biosimilar drugs will not always require tests for immune responses, drug action in the body, or comparative efficacy.
  • Faster Drug Approval: The changes could reduce the time needed for biosimilar drugs to be approved for sale.
  • Potential Lower Treatment Costs: Greater availability of cheaper alternatives may lead to lower drug expenditures for patients and healthcare systems.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Paul, Rand [R-KY].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

Analysis and Potential Impact of S 1414

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health